# Development of Broad Coronavirus Immunity Targeting the Fusion Peptide

> **NIH NIH R21** · WISTAR INSTITUTE · 2022 · $228,788

## Abstract

Project Summary
This revised application was originally responding to the Emergency Award ‘Rapid Investigation of Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)’
submitted through PAR-20-177. However, we are submitting the revised application, upon advice from NIH, to
the parent PA-20-195 with a due date of Nov 16th 2020. The application is titled ‘Development of Broad
Coronavirus Immunity Targeting the Fusion Peptide’. The assembled team brings together highly
complementary expertise in order to develop a unique coronavirus vaccine approach to provide more effective,
focused and broadened humoral immunity. This proposal focuses on the fusion peptide site of
vulnerability as it has been understudied, it is highly conserved and recently been identified as an
epitope of neutralizing antibodies in human convalescent sera. The project aims are: (1) Develop pan-
coronavirus fusion peptide nanoparticle and trimer immunogens (2) Develop immunization regimes to induce
broadly neutralizing antibodies using nucleic acid delivery.

## Key facts

- **NIH application ID:** 10424573
- **Project number:** 5R21AI158777-02
- **Recipient organization:** WISTAR INSTITUTE
- **Principal Investigator:** Daniel Kulp
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $228,788
- **Award type:** 5
- **Project period:** 2021-06-09 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10424573

## Citation

> US National Institutes of Health, RePORTER application 10424573, Development of Broad Coronavirus Immunity Targeting the Fusion Peptide (5R21AI158777-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10424573. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*